AUROPHARMA - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 4.0
Show all parameters (20 more)
🏭 Industry
The generic pharmaceutical industry is characterized by intense competition and regulatory scrutiny, however, companies with strong manufacturing capabilities and a diversified product portfolio, as seems to be the case here, often demonstrate pricing power and resilience. Margin compression remains a significant risk due to increased R&D costs and competitive pressures but a positive FDA inspection result mitigates some operational risks.
✅ Positive
The company demonstrates consistent profitability with a PAT growth of 31.8% year-over-year, reaching 737 Cr in the latest quarter. Furthermore, the debt to equity ratio of 0.19 indicates a conservative capital structure and strong balance sheet resilience.
⚠️ Limitation
Despite strong earnings growth, the high P/E ratio of 37.1 relative to its industry average of 34.6 suggests potential overvaluation. The relatively modest ROCE of 13% also leaves room for margin expansion and operational improvements, particularly considering the competitive pressures within the generic pharmaceutical sector.
🧾 Long-Term Outlook
We recommend an entry zone between 1,600 ₹ and 1,650 ₹ based on the current undervaluation relative to its industry peers. This reflects the recent FDA clearance providing further confidence in operations. Long-term holding guidance involves monitoring margin trends closely alongside continued expansion of revenue streams through new product launches and strategic acquisitions within key therapeutic areas—a hold rating is justified given the robust balance sheet and solid growth trajectory, contingent upon maintaining operational efficiency and navigating competitive dynamics.